Search results for "Chronic Obstructive"

showing 10 items of 321 documents

Comorbidities of Lung Disease in the Elderly

2017

Comorbidities are common in elderly individuals with chronic respiratory diseases. They can affect disease manifestations and severity and can even impact management. Comorbidities can affect the treatment of the lung disease, particularly because of the interaction with the respiratory drugs. Thus, a multidimensional approach with multidisciplinary intervention is suggested for elderly respiratory patients, switching from a disease-oriented scheme to a dysfunction-oriented approach. Unfortunately, older individuals are often excluded from clinical trials because of advanced age and comorbidities. This article reviews the role of comorbidities in the management of respiratory diseases in th…

Agingmedicine.medical_specialtyRespiratory Tract DiseasesComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineHumansSenile lung030212 general & internal medicineRespiratory systemIdiopathic lung fibrosiIntensive care medicineRespiratory Tract DiseaseAgedAsthmabusiness.industryChronic obstructive pulmonary diseasefood and beveragesmedicine.diseaseComorbidityAsthmaPatient Care ManagementClinical trial030228 respiratory systemLung diseaseGeriatrics and GerontologybusinessHumanClinics in Geriatric Medicine
researchProduct

Mild to moderate chronic airways disease does not carry an excess risk of cognitive dysfunction

2003

Whether chronic obstructive pulmonary disease (COPD) carries a risk of cognitive dysfunction prior to the onset of arterial hypoxemia is not known. Our objective was to assess both the prevalence and main correlates of subclinical cognitive dysfunction in older patients with non-hypoxemic COPD.Home-dwelling non-demented subjects over 64 years of age consecutively attending 24 outpatient Departments of Respiratory Medicine or Geriatrics because of COPD (N = 233), asthma (N = 203), non-obstructive bronchitis (N = 92) or chronic non-respiratory and non-dementing diseases (controls, N = 1080) underwent a multidimensional assessment. Cognitive status was assessed by the Mini-Mental State Examina…

Agingmedicine.medical_specialtyVital capacityNeuropsychological TestsSeverity of Illness IndexPulmonary Disease Chronic ObstructiveRisk FactorsInternal medicineSeverity of illnessmedicineHumansRespiratory functionAgedAsthmaAged 80 and overGeriatricsCOPDbusiness.industrymedicine.diseaseMultivariate AnalysisPhysical therapyBronchitisGeriatric Depression ScaleGeriatrics and GerontologyCognition DisordersbusinessAging Clinical and Experimental Research
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - G…

2016

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringin…

Allergic Rhinitislcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineManifestomedicine.medical_specialtyAllergyChronic Obstructive Pulmonary DiseaseImmunologyMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato Respiratoriosmall airways asthma aerosolBiochemistry03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology/dk/atira/pure/subjectarea/asjc/2700/2723Position Article and GuidelinesmedicineImmunology and Allergy030212 general & internal medicinesmall airwayIntensive care medicineAsthmaCOPDLungbusiness.industryasthma airway inflammationOrganic Chemistrysmall airways asthma control aerosol1103 Clinical SciencesChronic Obstructive Pulmonary Disease Patientasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemPhysical therapylcsh:RC581-607AirwaybusinesscontrolThe World Allergy Organization Journal
researchProduct

Outcome and attitudes toward home tracheostomy ventilation of consecutive patients: a 10-year experience.

2008

Summary Objectives To describe survival, predictors of long-term outcome and attitudes in patients treated at home by tracheostomy-intermittent positive-pressure ventilation (TIPPV) for respiratory failure during a 10-year period (1995–2004). Methods Seventy-seven consecutive patients were treated by TIPPV at home. Patients were divided into three groups: neuromuscular, pulmonary, and non-pulmonary patients. Effects of TIPPV on survival, factors influencing outcome after TIPPV, and attitudes of patients and caregivers regarding mechanical ventilation were studied. Results Forty-one patients (53%) were neuromuscular, 19 (25%) were affected by pulmonary diseases, and 17 (22%) by non-pulmonary…

Artificial ventilationPulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySurvivalHome Nursingmedicine.medical_treatmentRespiratory failureIntermittent Positive-Pressure VentilationPulmonary Disease Chronic ObstructiveTracheotomyTracheostomyInternal medicinemedicineCOPDHumansProspective StudiesProspective cohort studySurvival rateAgedMechanical ventilationAged 80 and overCOPDbusiness.industryTracheostomy mechanical ventilationRespiratory diseaseAmyotrophic Lateral SclerosisNeuromuscular DiseasesMiddle Agedmedicine.diseaseRespiration ArtificialSurgerySurvival RateCaregiversRespiratory failureFemaleALSbusinessRespiratory InsufficiencyAttitude to HealthRespiratory medicine
researchProduct

GOLD Staging System is Appropriate to Predict Mortality in Older People With Chronic Obstructive Pulmonary Disease

2018

Abstract Introduction In the new GOLD classification the reduction of FEV1, expressed as percentage of predicted value (FEV1PP), is considered an important prognostic factor. However, the use of FEV1PP may introduce bias, especially if based on equations derived from populations different from the one under study. We evaluated how well the GOLD classification stratifies the mortality risk when FEV1PP is based on an equation developed in the same population that gave rise to cases, externally developed equations, or as FEV1 divided by cubed height (FEV1/Ht3). Methods We studied 882 participants aged ≥65 years. Bronchial obstruction was defined using a fixed cut-off of 0.7 for FEV1/FVC. Predi…

BODE indexPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesFEV1/FVC ratioFEV10302 clinical medicineElderlyInternal medicinemedicine030212 general & internal medicineGOLDeducationStaging systemCOPDeducation.field_of_studybusiness.industryChronic obstructive pulmonary diseaseHazard ratioGeneral Medicinerespiratory systemmedicine.diseaserespiratory tract diseases030228 respiratory systemQuartilebusiness
researchProduct

The anti-inflammatory properties of tiotropium

2018

BenzoxazinePulmonary and Respiratory Medicinemedicine.drug_classbusiness.industryScopolamine DerivativesPulmonary diseaseTiotropium bromidePharmacologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-inflammatory03 medical and health sciencesAnti-Inflammatory AgentPulmonary Disease Chronic ObstructiveScopolamine Derivative0302 clinical medicine030228 respiratory systemDouble-Blind Methodmedicine030212 general & internal medicineTiotropium Bromidebusinessmedicine.drugHuman
researchProduct

Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers

2014

Background Nanomedicine studies have showed a great potential for drug delivery into the lung. In this manuscript nanostructured lipid carriers (NLC) containing Fluticasone propionate (FP) were prepared and their biocompatibility and effects in a human bronchial epithelial cell line (16-HBE) stimulated with cigarette smoke extracts (CSE) were tested. Results Biocompatibility studies showed that the NLC did not induce cell necrosis or apoptosis. Moreover, it was confirmed that CSE increased intracellular ROS production and TLR4 expression in bronchial epithelial cells and that FP-loaded NLC were more effective than free drug in modulating these processes. Finally, the nanoparticles increased…

BiocompatibilityCellBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceApoptosisBronchiBioengineeringChronic obstructive pulmonary disease; Asthma; hronic obstructive pulmonary disease.PharmacologyFluticasone propionatemedicine.disease_causeApplied Microbiology and BiotechnologyNanostructured lipid carriers Corticosteroid Fluticasone propionate Cigarette smoke Airway epithelial cell Chronic obstructive pulmonary disease Asthmachemistry.chemical_compoundAirway epithelial cellmedicineHumansCorticosteroidCells CulturedFluticasoneDrug CarriersNanostructured lipid carriersbusiness.industryResearchChronic obstructive pulmonary diseaseSmokingCigarette smokeEpithelial CellsGlutathioneGlutathioneLipidsAsthmaNanostructuresToll-Like Receptor 4medicine.anatomical_structurechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoApoptosisDrug deliveryFluticasoneMolecular MedicineReactive Oxygen SpeciesbusinessOxidative stressIntracellularmedicine.drugJournal of Nanobiotechnology
researchProduct

N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A…

2011

64% of chronic obstructive pulmonary disease (COPD) exacerbations are caused by respiratory infections including influenza (strains A and B) and respiratory syncytial virus (RSV). They affect the airway epithelium increasing inflammatory and apoptosis events through mechanisms involving ROS generation, and induce the release of mucins from epithelial cells that are involved in the deterioration of the patient's health during the course of the disease. The antioxidant NAC has proved useful in the management of COPD reducing symptoms, exacerbations and accelerated lung function decline. It has been shown to inhibit influenza virus replication and to diminish the release of inflammatory and ap…

BiologyMucin 5ACmedicine.disease_causeVirus ReplicationBiochemistryp38 Mitogen-Activated Protein KinasesVirusCell LinePulmonary Disease Chronic ObstructivemedicineHumansInterleukin 8PhosphorylationPharmacologyA549 cellMucinNF-kappa BAcetylcysteineRespiratory Syncytial VirusesPulmonary AlveoliInfluenza B virusRespiratory syncytial virus (RSV)Viral replicationApoptosisInfluenza A virusImmunologyRespiratory epitheliumInflammation MediatorsBiochemical pharmacology
researchProduct

IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: Effect of Tiotropium

2016

Abstract Aims IL-17A plays a key role in the persistence of airway inflammation, oxidative stress, and reduction of steroid-sensitivity in COPD. We studied the effect of IL-17A on chromatin remodeling and IL-8 production. Main methods We measured the levels of IL-8 and IL-17A in induced sputum supernatants (ISS) from healthy controls (HCs), healthy smokers (HSs), and COPD patients by enzyme-linked immunosorbent assay (ELISA). A human bronchial epithelial cell line (16HBE) was stimulated with ISS from HCs, HSs, or COPD subjects. IL-8 was evaluated in 16HBE by Western blot and real-time polymerase chain reaction (PCR). Histone deacetylase 2 (HDAC2), acetyl histone H3 (Ac-His H3) (k9) and inhi…

Bronchial epithelial cell0301 basic medicineHistone Deacetylase 2BronchiBiologyGeneral Biochemistry Genetics and Molecular BiologyChromatin remodelingProinflammatory cytokineHistonesChromatin remodelingAndrologyPulmonary Disease Chronic Obstructive03 medical and health sciencesHistone H3Western blotIL-17AmedicineHumansInterleukin 8Tiotropium BromideGeneral Pharmacology Toxicology and PharmaceuticsCells CulturedCOPDBiochemistry Genetics and Molecular Biology (all)IL-8medicine.diagnostic_testHistone deacetylase 2Chronic obstructive pulmonary diseaseAnti-Inflammatory Agents Non-SteroidalInterleukin-17Interleukin-8SmokingSputumEpithelial CellsGeneral MedicineChromatin Assembly and Disassemblymedicine.diseaserespiratory tract diseases030104 developmental biologyPharmacology Toxicology and Pharmaceutics (all)ImmunologyInterleukin 17human activitiesLife Sciences
researchProduct